Re-induction and targeted conditioning with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] leads to high rates of transplantation and successful engraftment in older patients with active, relapsed or refractory (rel/ref) AML after failure of chemotherapy and targeted agents: Preliminary midpoint results from the prospective, randomized phase 3 Sierra Trial Meeting Abstract
| Authors: | Gyurkocza, B.; Nath, R.; Stiff, P. J.; Agura, E.; Litzow, M.; Tomlinson, B.; Choe, H. K.; Abhyankar, S.; Seropian, S.; Chen, G. L.; Hari, P.; Al-Kadhimi, Z. S.; Foran, J. M.; Orozco, J.; Van Besien, K.; Sabloff, M.; Kebriaei, P.; Levy, M. Y.; Lazarus, H. M.; Giralt, S. A.; Berger, M. S.; Reddy, V.; Pagel, J. M. |
| Abstract Title: | Re-induction and targeted conditioning with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] leads to high rates of transplantation and successful engraftment in older patients with active, relapsed or refractory (rel/ref) AML after failure of chemotherapy and targeted agents: Preliminary midpoint results from the prospective, randomized phase 3 Sierra Trial |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164607031 |
| DOI: | 10.1182/blood-2019-122776 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 5642 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work